A probe by Finra, Wall Street’s self-regulator, spans the wealth unit as well as the division that houses trading.

Pharvaris N.V. ('Pharvaris,” Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to address unmet needs of those living with ...